Vera Therapeutics, Inc. Class A Common Stock
VERAVera Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for autoimmune and inflammatory diseases. The company is dedicated to advancing novel biologics targeting specific pathways to address unmet medical needs, aiming to improve patient outcomes in conditions such as kidney diseases and other chronic inflammatory disorders.
Company News
Vera Therapeutics announced that William Turner, current Chief Regulatory Officer, will retire and transition to Strategic Advisor role in Q3 2026. Nancy Boman, M.D., Ph.D., with over 25 years of regulatory affairs experience, will succeed him. The transition follows the recent accelerated FDA approval of TRUTAKNA (atacicept-vymj), the company's ...
Rhenman & Partners Asset Management AB sold its entire 420,000-share stake in Vera Therapeutics (VERA) during Q1 2026, valued at approximately $18.1 million. The position, which represented 2.0% of the fund's assets in the prior quarter, was fully exited. Despite the sale, Vera Therapeutics stock has surged 81.4% over the past year and outperform...
The IgA Nephropathy (IgAN) market is projected to grow at 18.6% CAGR through 2036, driven by rising disease prevalence, improved diagnostics, and a robust pipeline of novel immunotherapies. The market was valued at $1.5 billion in 2025, with recent FDA approvals including VOYXACT and multiple late-stage candidates from major pharmaceutical compan...
The idiopathic membranous nephropathy (IMN) market is expected to grow from USD 130 million in 2025 to USD 1 billion by 2036, driven by rising disease prevalence, improved diagnostics, and emerging targeted therapies. Multiple pharmaceutical companies are advancing novel treatments including SNP-ACTH (1-39) Gel, zanubrutinib, obinutuzumab, and po...
Deerfield Management Company increased its stake in Vera Therapeutics by 418,538 shares during Q4 2025, bringing its total position to $205.58 million (2.6% of fund AUM). Vera's stock has surged 50% over the past year as its lead drug candidate atacicept approaches an FDA decision on July 7, 2026, for treating IgA nephropathy. The company has suf...
